S. Sherman Jeffrey's most recent trade in Neogenomics Inc. was a trade of 42,158 Common Stock done . Disclosure was reported to the exchange on Feb. 21, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2026 | 42,158 | 218,986 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 21 Feb 2026 | 42,158 | 84,318 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 21 Feb 2026 | 15,535 | 15,536 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2026 | 15,535 | 223,792 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2026 | 10,729 | 208,257 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2026 | 3,783 | 220,009 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 07 Dec 2025 | 11,938 | 176,394 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.62 per share. | 06 Aug 2025 | 20,000 | 188,332 (0%) | 0% | 5.6 | 112,322 | Common Stock |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2025 | 13,005 | 171,499 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 11 May 2025 | 13,005 | 13,006 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 11 May 2025 | 3,167 | 168,332 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 7.51 per share. | 02 May 2025 | 20,000 | 158,494 (0%) | 0% | 7.5 | 150,104 | Common Stock |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 21 Feb 2025 | 214,900 | 214,900 | - | - | Stock Option (Right to Buy) | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 21 Feb 2025 | 126,476 | 126,476 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 21 Feb 2025 | 15,535 | 31,071 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 15,535 | 141,271 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 4,207 | 137,064 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 14 Jan 2025 | 59,382 | 59,382 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 07 Dec 2024 | 11,746 | 123,754 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 138,667 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 11 May 2024 | 13,005 | 26,011 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 148,505 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 11 May 2024 | 13,005 | 26,011 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 13,005 | 138,667 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 3,167 | 135,500 (0%) | 0% | 14.9 | 47,062 | Common Stock |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 3,167 | 135,500 (0%) | 0% | 14.9 | 47,062 | Common Stock |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 23 Feb 2024 | 77,913 | 77,913 | - | - | Stock Option (Right to Buy) | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 23 Feb 2024 | 46,606 | 46,606 | - | - | Performance Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 23 Feb 2024 | 46,606 | 46,606 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 07 Dec 2023 | 8,147 | 125,662 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 11 May 2023 | 73,016 | 73,016 | - | - | Stock Option (Right to Buy) | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 11 May 2023 | 39,016 | 39,016 | - | - | Performance Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 11 May 2023 | 39,016 | 39,016 | - | - | Restricted Stock Unit | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | 05 Dec 2022 | 249,169 | 249,169 | - | - | Stock Option (Right to Buy) | ||
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 89,206 | 133,809 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc | Mr. Jeffrey S. Sherman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 44,603 | 44,603 (0%) | 0% | 0 | Common Stock | |
| Privia Health Group Inc | Mr. Jeffrey S. Sherman | EVP, CFO and CAO | 05 Jan 2022 | 235,128 | 235,128 | - | - | Stock Option (Right to Purchase) | ||
| Privia Health Group Inc | Mr. Jeffrey S. Sherman | EVP, CFO and CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 61,307 | 61,307 | - | 0 | Common Stock, $0.01 par value per share |